|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
pre-filled pen
pre-filled syringe
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:C10AX14
|
|
gptkbp:brand
|
gptkb:Praluent
|
|
gptkbp:CASNumber
|
gptkb:1245916-14-6
|
|
gptkbp:contraindication
|
hypersensitivity to alirocumab
|
|
gptkbp:developedBy
|
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:drugClass
|
lipid-lowering agent
|
|
gptkbp:effect
|
lowers LDL cholesterol
reduces risk of cardiovascular events
|
|
gptkbp:form
|
solution for injection
150 mg
75 mg
|
|
gptkbp:frequency
|
every 4 weeks
every 2 weeks
|
|
gptkbp:genericName
|
gptkb:alirocumab
|
|
gptkbp:halfLife
|
17-20 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Praluent (alirocumab)
|
|
gptkbp:indication
|
gptkb:familial_hypercholesterolemia
gptkb:heterozygous_familial_hypercholesterolemia
atherosclerotic cardiovascular disease
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:PCSK9
|
|
gptkbp:marketedIn
|
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
PCSK9 inhibitor
|
|
gptkbp:monoclonalAntibodyType
|
gptkb:IgG1
|
|
gptkbp:origin
|
human monoclonal antibody
|
|
gptkbp:patent
|
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescribes
|
adults
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
injection site reaction
allergic reactions
nasopharyngitis
flu-like symptoms
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:bfsParent
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|